Patients compliance in hypertension‐the importance of number of tablets.

Asplund, Johan; Danielson, Mats

doi:10.1111/j.1365-2125.1984.tb02388.x

Cited by 27 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patient education by the physician is an important factor in helping to improve patient compliance and there is a wealth of data available to support this contention [15,[16][17][18][19][20][21][22]. Gatley [16] showed, as early as 1968, that once-daily dosing was to be preferred to multiple dosing whenever possible.…”

Section: Discussionmentioning

confidence: 99%

Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension

Detry¹,

Block

Backer

et al. 1995

Eur J Clin Pharmacol

View full text Add to dashboard Cite

To study patient compliance in hypertensive outpatients amlodipine (5 mg once daily) and slow release nifedipine (20 mg twice daily) were compared in an open, crossover study in general practices. Four methods of assessment for patient compliance (pill count, taking compliance, days with correct dosing, timing compliance) were used in both study arms. For the latter three assessment a special device, the medication event monitoring system, was used to record the time and date of each opening and closure of the container. The compliance of the 320 hypertensive patients with once-daily amlodipine was markedly superior to twice-daily slow release nifedipine. Therapeutic coverage was also significantly better for amlodipine in the hypertensive patients. Amlodipine was better tolerated than nifedipine slow release. Patient compliance and therapeutic coverage with the calcium antagonist amlodipine given once daily was superior to slow release nifedipine b.d. in hypertensive outpatients recruited in general practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension

Detry¹,

Block

Backer

et al. 1995

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Three cohort studies 9,25,26 (nϭ17 642) and 2 trials 18,20 (nϭ357) reported data on compliance among 17 999 hypertensive patients ( Figure 2). In the cohort studies, the use of an FDC was associated with a 21% increase in compliance with medications as compared with the use of the free-drug combination (OR: 1.21 [95% CI: 1.00 to 1.47]).…”

Section: Compliance and Persistence With Therapymentioning

confidence: 99%

Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents

2010

View full text Add to dashboard Cite

Abstract-Two or more antihypertensive agents are increasingly used to control blood pressure (BP) in hypertensive patients. However, it is unclear whether fixed-dose combinations (FDCs) of 2 antihypertensive agents in a single tablet provide greater benefits than the corresponding free-drug components given separately. A meta-analysis was performed to assess compliance, persistence, BP control, and safety associated with FDCs in comparison with their free-drug components. Fifteen included studies (nϭ32331) reported on Ն1 of the evaluated outcomes. In 3 cohort studies and 2 trials reporting on drug compliance (nϭ17 999), the use of FDCs was associated with significantly better compliance (odds ratio: Pϭ0.19). In 9 trials (nϭ1671) with BP data, use of an FDC was associated with nonsignificant changes in systolic and diastolic BPs of 4.1 mm Hg (95% CI: Ϫ9.8 to 1.5; Pϭ0.15) and 3.1 mm Hg (95% CI: Ϫ7.1 to 0.9; Pϭ0.13), respectively. In these BP-lowering comparisons, there was heterogeneity associated with differences in study design but no publication bias. In conclusion, compared with free-drug combinations, FDCs of antihypertensive agents are associated with a significant improvement in compliance and with nonsignificant beneficial trends in BP and adverse effects. (Hypertension. 2010;55:399-407.)

show abstract

“…A 24-h urine sample was collected, and volume, creatinine, and albumin were measured. We used the homeostasis model assessment to estimate insulin resistance (HOMA-IR) (24).…”

mentioning

confidence: 99%

Chromium Treatment Has No Effect in Patients With Type 2 Diabetes in a Western Population

Kleefstra

Houweling²,

Bakker

et al. 2007

Diabetes Care

View full text Add to dashboard Cite

OBJECTIVE -Chromium treatment has been reported to improve glycemic control in patients with type 2 diabetes. However, concern exists about the possible toxic effects of chromium picolinate. The aim of this study was to determine the effect of chromium treatment in the form of chromium yeast on glycemic control in a Western population of patients with type 2 diabetes who were being treated with oral hypoglycemic agents.RESEARCH DESIGN AND METHODS -In this 6-month, double-blind study, patients with moderate glycemic control, being treated with oral hypoglycemic agents, were randomly assigned to receive either a placebo or treatment with 400 g of chromium daily in the form of chromium yeast. The primary efficacy parameter was a change in A1C. Secondary end points were changes in lipid profile, BMI, blood pressure, body fat, and insulin resistance.RESULTS -No differences were found for the change in A1C between the intervention and placebo groups, nor were any differences found between the groups for the secondary end points.CONCLUSIONS -There is no evidence that chromium in the form of chromium yeast is effective in improving glycemic control in Western patients with type 2 diabetes who are taking oral hypoglycemic agents. Diabetes Care 30:1092-1096, 2007T ype 2 diabetes is a chronic, progressive illness that causes considerable morbidity and premature mortality (1,2). The worldwide prevalence of type 2 diabetes is high and is increasing steadily (3). The majority of patients are insulin resistant (4). Although these patients may be treated with well-established hypoglycemic agents, studying alternative treatment options directed toward improving insulin sensitivity is important.For many decades, we have known that chromium plays a role in glucose metabolism, and, as early as 1957, it was already being referred to as "a glucose tolerance factor" (5). In vitro and animal studies have shown that chromium improves insulin resistance (6,7). One of the intracellular proteins that influences the insulin receptor is the oligopeptide apolipoprotein low-molecular weight chromium-binding substance (Apochromomodulin) (7). This peptide has the ability to increase tyrosine kinase activity eightfold, depending on the chromium concentration (8), thus strengthening the idea that chromium plays an influential role in glucose metabolism (5).The largest study (n ϭ 180) to date investigating the effect of chromium in patients with type 2 diabetes was published by Anderson et al. (9). They found that the A1C of Chinese patients treated with 1,000 g of chromium in the form of chromium picolinate decreased almost 2 percentage points compared with a placebo group after 4 months. However, two systematic reviews that addressed the effects of chromium on glycemic control concluded that, on the basis of the currently available data, the effects of chromium on glycemic control are inconclusive (10,11). Randomized studies with results on glucose, insulin, and/or A1C were collected by Althuis et al. (10) in their review. Reasons for the inconcl...

show abstract

Patients compliance in hypertension‐the importance of number of tablets.

Cited by 27 publications

References 8 publications

Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension

Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension

Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents

Chromium Treatment Has No Effect in Patients With Type 2 Diabetes in a Western Population

Contact Info

Product

Resources

About